JOP20200045A1 - كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين - Google Patents

كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين

Info

Publication number
JOP20200045A1
JOP20200045A1 JOP/2020/0045A JOP20200045A JOP20200045A1 JO P20200045 A1 JOP20200045 A1 JO P20200045A1 JO P20200045 A JOP20200045 A JO P20200045A JO P20200045 A1 JOP20200045 A1 JO P20200045A1
Authority
JO
Jordan
Prior art keywords
adults
synthetic
treatment
cannabidiol
focal epilepsy
Prior art date
Application number
JOP/2020/0045A
Other languages
English (en)
Inventor
Donna Gutterman
John Messenheimer
Terri Sebree
Ted Smith
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of JOP20200045A1 publication Critical patent/JOP20200045A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

غير متوفر
JOP/2020/0045A 2017-09-19 2018-09-18 كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين JOP20200045A1 (ar)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762560446P 2017-09-19 2017-09-19
US201762593575P 2017-12-01 2017-12-01
US201862613160P 2018-01-03 2018-01-03
US201862652995P 2018-04-05 2018-04-05
US201862660198P 2018-04-19 2018-04-19
PCT/IB2018/057189 WO2019058261A1 (en) 2017-09-19 2018-09-18 TRANSDERMAL SYNTHETIC CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS

Publications (1)

Publication Number Publication Date
JOP20200045A1 true JOP20200045A1 (ar) 2020-02-27

Family

ID=63762572

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0045A JOP20200045A1 (ar) 2017-09-19 2018-09-18 كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين

Country Status (11)

Country Link
US (2) US20190083388A1 (ar)
EP (1) EP3684411A1 (ar)
JP (2) JP2020534362A (ar)
KR (1) KR20200055067A (ar)
AU (1) AU2018337933A1 (ar)
BR (1) BR112020004947A2 (ar)
CA (1) CA3075719A1 (ar)
IL (2) IL301910A (ar)
JO (1) JOP20200045A1 (ar)
MX (1) MX2020003004A (ar)
WO (1) WO2019058261A1 (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3733156A1 (de) * 2019-05-02 2020-11-04 Gábor Fóti C.b.d.m therapie
MX2022003193A (es) * 2019-09-17 2022-04-11 Zynerba Pharmaceuticals Inc Tratamiento de encefalopatia asociada al gen syngap1.
CA3155176A1 (en) * 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
GB2597287A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
CN115884761A (zh) * 2020-08-17 2023-03-31 长矛治疗股份有限公司 大麻素的透皮药物制剂
CN117479930A (zh) * 2021-04-08 2024-01-30 长矛治疗股份有限公司 用于治疗癫痫发作病症的药物组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127033A1 (en) 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
LT2473475T (lt) * 2009-08-31 2017-08-10 Zynerba Pharmaceuticals, Inc. Kanabidiolio provaisto panaudojimas vietiniam arba transderminiam įvedimui su mikroadatomis
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
JP2023171776A (ja) 2023-12-05
US20190083388A1 (en) 2019-03-21
EP3684411A1 (en) 2020-07-29
KR20200055067A (ko) 2020-05-20
AU2018337933A1 (en) 2020-03-12
JP2020534362A (ja) 2020-11-26
IL301910A (en) 2023-06-01
WO2019058261A9 (en) 2019-07-04
MX2020003004A (es) 2020-11-06
IL272818A (en) 2020-04-30
US20210030665A1 (en) 2021-02-04
CA3075719A1 (en) 2019-03-28
BR112020004947A2 (pt) 2020-09-15
WO2019058261A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
MX2020003004A (es) Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.
MX2020006954A (es) Uso del cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
PH12015502075A1 (en) Treatment of cataplexy
PH12017500933A1 (en) Sublingual administration of riluzole
MY194341A (en) Method of treating a brain tumor
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
MX2017006446A (es) Administracion sublingual de riluzol.
MX2018004132A (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
NZ722600A (en) Methods of treating mild brain injury
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
EA201690997A1 (ru) Композиция для применения в лечении стойкого кашля
MX357763B (es) Tratamiento para cancer pancreatico.
MX2015013186A (es) Adminitracion craneal de productos farmaceuticos.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2018011379A (es) Tratamiento del prurito uremico.
MX2018001684A (es) Metodo de curacion de heridas.
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.
EA201891008A2 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
MX2016002307A (es) Tratamiento para el cancer.
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
NZ703905A (en) Method of treating multiple sclerosis by using narrow band uvb